

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 August 2001 (30.08.2001)

PCT

(10) International Publication Number
WO 01/62756 A1

(51) International Patent Classification⁷: **C07D 401/04**,
407/14, 401/14, 413/14, 409/14, 471/04, 417/14, A61K
31/44, 31/415 // (C07D 401/14, 233:00, 213:00) (C07D
407/14, 317:00, 233:00, 213:00)

(21) International Application Number: **PCT/GB01/00736**

(22) International Filing Date: 21 February 2001 (21.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0004053.5 21 February 2000 (21.02.2000) GB
0015902.0 28 June 2000 (28.06.2000) GB

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM P.L.C. [GB/GB]; New
Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **GASTER, Laramie, Mary** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). **HADLEY, Michael, Stewart** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). **HARLING, John, David** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). **HARRINGTON, Frank, Peter** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South,

Third Avenue, Harlow, Essex CM19 5AW (GB). **HEER, Jag, Paul** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). **HEIGHTMAN, Thomas, Daniel** [GB/GB]; GlaxoSmithKline, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB).

(74) Agent: **BLAKEY, Alison, Jane**; Corporate Intellectual Property, GlaxoSmithKline, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/62756 A1

(54) Title: PYRIDINYLIMIDAZOLES



(57) Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R₁, R₂ and R₃ represent various functional groups, and one of X₁ and X₂ is N and the other is NR₁₀; and their use as pharmaceuticals.

PYRIDINYLMIDAZOLES

This invention relates to pyridyl substituted imidazoles which are inhibitors of the transforming growth factor, ("TGF")- β signaling pathway, in particular, the phosphorylation of smad2 or smad3 by the type I or activin-like kinase ("ALK")-5 receptor, methods for their
5 preparation and their use in medicine, specifically in the treatment and prevention of a disease state mediated by this pathway.

TGF- β 1 is the prototypic member of a family of cytokines including the TGF- β s, activins, inhibins, bone morphogenetic proteins and Müllerian-inhibiting substance, that signal through a family of single transmembrane serine/threonine kinase receptors. These receptors can
10 be divided in two classes, the type I or activin like kinase (ALK) receptors and type II receptors. The ALK receptors are distinguished from the type II receptors in that the ALK receptors (a) lack the serine/threonine rich intracellular tail, (b) possess serine/threonine kinase domains that are very homologous between type I receptors, and (c) share a common sequence motif called the GS domain, consisting of a region rich in glycine and serine residues. The GS domain is at the amino
15 terminal end of the intracellular kinase domain and is critical for activation by the type II receptor. Several studies have shown that TGF- β signaling requires both the ALK and type II receptors. Specifically, the type II receptor phosphorylates the GS domain of the type I receptor for TGF- β , ALK5, in the presence of TGF- β . The ALK5, in turn, phosphorylates the cytoplasmic proteins smad2 and smad3 at two carboxy terminal serines. Generally it is believed
20 that in many species, the type II receptors regulate cell proliferation and the type I receptors regulate matrix production. Therefore, preferred compounds of this invention are selective in that they inhibit the type I receptor and thus matrix production, and not the type II receptor mediated proliferation.

Activation of the TGF- β 1 axis and expansion of extracellular matrix are early and
25 persistent contributors to the development and progression of chronic renal disease and vascular disease. Border W.A., Noble N.A., *N. Engl. J. Med.*, Nov. 10, 1994; 331(19):1286-92. Further, TGF- β 1 plays a role in the formation of fibronectin and plasminogen activator inhibitor-1, components of sclerotic deposits, through the action of smad3 phosphorylation by the TGF- β 1 receptor ALK5. Zhang Y., Feng X.H., Derynck R., *Nature*, Aug. 27, 1998; 394(6696):909-13;
30 Usui T., Takase M., Kaji Y., Suzuki K., Ishida K., Tsuru T., Miyata K., Kawabata M., Yamashita H., *Invest. Ophthalmol. Vis. Sci.*, Oct. 1998; 39(11):1981-9.

Progressive fibrosis in the kidney and cardiovascular system is a major cause of suffering and death and an important contributor to the cost of health care. TGF- β 1 has been implicated in many renal fibrotic disorders. Border W.A., Noble N.A., *N. Engl. J. Med.*, Nov 10, 1994;
35 331(19):1286-92. TGF- β 1 is elevated in acute and chronic glomerulonephritis, Yoshioka K., Takemura T., Murakami K., Okada M., Hino S., Miyamoto H., Maki S., *Lab. Invest.*, Feb. 1993; 68(2):154-63, diabetic nephropathy, Yamamoto, T., Nakamura, T., Noble, N.A., Ruoslahti, E., Border, W.A., (1993) *PNAS* 90:1814-1818, allograft rejection, HIV nephropathy and angiotensin-induced nephropathy, Border W.A., Noble N.A., *N. Engl. J. Med.*, Nov. 10, 1994;
40 331(19):1286-92. In these diseases the levels of TGF- β 1 expression coincide with the production of extracellular matrix. Three lines of evidence suggest a causal relationship between TGF- β 1 and the production of matrix. First, normal glomeruli, mesangial cells and non-renal cells can be induced to produce extracellular-matrix protein and inhibit protease activity by exogenous TGF-

$\beta 1$ in vitro. Second, neutralizing anti-bodies against TGF- $\beta 1$ can prevent the accumulation of extracellular matrix in nephritic rats. Third, TGF- $\beta 1$ transgenic mice or in vivo transfection of the TGF- $\beta 1$ gene into normal rat kidneys resulted in the rapid development of glomerulosclerosis. Kopp J.B., Factor V.M., Mozes M., Nagy P., Sanderson N., Bottinger E.P., Klotman P.E.,
 5 Thorgeirsson S.S., *Lab Invest*, June 1996; 74(6):991-1003. Thus, inhibition of TGF- $\beta 1$ activity is indicated as a therapeutic intervention in chronic renal disease.

TGF- $\beta 1$ and its receptors are increased in injured blood vessels and are indicated in neointima formation following balloon angioplasty, Saltis J., Agrotis A., Bobik A., *Clin Exp Pharmacol Physiol*, Mar. 1996; 23(3):193-200. In addition TGF- $\beta 1$ is a potent stimulator of
 10 smooth muscle cell ("SMC") migration in vitro and migration of SMC in the arterial wall is a contributing factor in the pathogenesis of atherosclerosis and restenosis. Moreover, in multivariate analysis of the endothelial cell products against total cholesterol, TGF- β receptor ALK5 correlated with total cholesterol ($P < 0.001$) Blann A.D., Wang J.M., Wilson P.B., Kumar S., *Atherosclerosis*, Feb. 1996; 120(1-2):221-6. Furthermore, SMC derived from human
 15 atherosclerotic lesions have an increased ALK5/TGF- β type II receptor ratio. Because TGF- $\beta 1$ is over-expressed in fibroproliferative vascular lesions, receptor-variant cells would be allowed to grow in a slow, but uncontrolled fashion, while overproducing extracellular matrix components McCaffrey T.A., Consigli S., Du B., Falcone D.J., Sanborn T.A., Spokojny A.M., Bush H.L., Jr., *J Clin Invest*, Dec. 1995; 96(6):2667-75. TGF- $\beta 1$ was immunolocalized to non-foamy
 20 macrophages in atherosclerotic lesions where active matrix synthesis occurs, suggesting that non-foamy macrophages may participate in modulating matrix gene expression in atherosclerotic remodeling via a TGF- β -dependent mechanism. Therefore, inhibiting the action of TGF- $\beta 1$ on ALK5 is also indicated in atherosclerosis and restenosis.

TGF- β is also indicated in wound repair. Neutralizing antibodies to TGF- $\beta 1$ have been
 25 used in a number of models to illustrate that inhibition of TGF- $\beta 1$ signaling is beneficial in restoring function after injury by limiting excessive scar formation during the healing process. For example, neutralizing antibodies to TGF- $\beta 1$ and TGF- $\beta 2$ reduced scar formation and improved the cytoarchitecture of the neoderms by reducing the number of monocytes and macrophages as well as decreasing dermal fibronectin and collagen deposition in rats Shah M., *J.*
 30 *Cell. Sci.*, 1995, 108, 985-1002. Moreover, TGF- β antibodies also improve healing of corneal wounds in rabbits Moller-Pedersen T., *Curr. Eye Res.*, 1998, 17, 736-747, and accelerate wound healing of gastric ulcers in the rat, Ernst H., *Gut*, 1996, 39, 172-175. These data strongly suggest that limiting the activity of TGF- β would be beneficial in many tissues and suggest that any disease with chronic elevation of TGF- β would benefit by inhibiting smad2 and smad3 signaling
 35 pathways.

TGF- β is also implicated in peritoneal adhesions Saed G.M., *et al*, *Wound Repair Regeneration*, 1999 Nov-Dec, 7(6), 504-510. Therefore, inhibitors of ALK5 would be beneficial in preventing peritoneal and sub-dermal fibrotic adhesions following surgical procedures.

TGF $\beta 1$ -antibodies prevent transplanted renal tumor growth in nude mice through what is
 40 thought to be an anti-angiogenic mechanism Ananth S., *et al*, *Journal Of The American Society Of Nephrology Abstracts*, 9: 433A(Abstract). While the tumor itself is not responsive to TGF- β , the surrounding tissue is responsive and supports tumor growth by neovascularization of the TGF- β

secreting tumor. Thus, antagonism of the TGF- β pathway should prevent metastasis growth and reduce cancer burden.

Bioorg. Med. Chem. Lett., 1995, 5(6), 543 discloses 2-[5-(2-methylphenyl)-2-propyl-1H-imidazol-4-yl]pyridine as an inhibitor of gastric H⁺/K⁺ ATPase.

5 DE 2221546 discloses the following compounds as antiinflammatory, analgesic or antipyretic agents:

2-[2-(1,1-dimethylethyl)-5-(4-methoxyphenyl)-1H-imidazol-4-yl]pyridine,

2-[2-(1,1-dimethylethyl)-5-phenyl-1H-imidazol-4-yl]pyridine.

Japanese Patent No. 09124640 discloses the following compounds as agrochemical fungicides:

10 2-[5-(3,5-dichlorophenyl)-2-methyl-1H-imidazol-4-yl]pyridine,

2-[5-(3,5-dimethylphenyl)-2-methyl-1H-imidazol-4-yl]pyridine,

2-[5-(3,5-dimethylphenyl)-2-ethyl-1H-imidazol-4-yl]pyridine,

2-[5-(3,5-dimethylphenyl)-2-amino-1H-imidazol-4-yl]pyridine,

2-[5-(3,5-dimethylphenyl)-2-isopropyl-1H-imidazol-4-yl]pyridine,


15 2-[5-(3,5-dimethylphenyl)-2-propyl-1H-imidazol-4-yl]pyridine,

2-[5-(3,5-dimethylphenyl)-2-carboxamide-1H-imidazol-4-yl]pyridine.

Surprisingly, it has now been discovered that a class of 2-pyridyl substituted imidazoles of formula (I), function as potent and selective non-peptide inhibitors of ALK5 kinase and therefore, have utility in the treatment and prevention of various disease states mediated by ALK5

20 kinase mechanisms, such as chronic renal disease, acute renal disease, wound healing, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers, ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, trophic conditions, atherosclerosis, peritoneal and sub-dermal adhesion, any disease wherein fibrosis is a major component, including, but not limited to lung fibrosis and liver fibrosis, and restenosis.

25 According to the invention there is provided a compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

30 wherein R₁ is naphthyl, anthracenyl, or phenyl optionally substituted with one or more substituents selected from the group consisting of halo, C₁₋₆alkoxy, C₁₋₆alkylthio, C₁₋₆alkyl, C₁₋₆haloalkyl, O-(CH₂)_m-Ph, S-(CH₂)_m-Ph, cyano, phenyl, and CO₂R, wherein R is hydrogen or C₁₋₆alkyl and m is 0-3; or R₁ is phenyl or pyridyl fused with an aromatic or non-aromatic cyclic ring of 5-7 members wherein said cyclic ring optionally contains up to three heteroatoms,

35 independently selected from N, O and S, and is optionally substituted by =O;

R₂ represents hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, phenyl, C₁₋₆haloalkyl, halo, NH₂, NH-C₁₋₆alkyl or NH(CH₂)_n-Ph wherein n is 0-3;

R₃ represents C₁₋₆alkyl, -(CH₂)_p-CN, -(CH₂)_p-COOH, -(CH₂)_p-CONHR₄R₅,

$-(CH_2)_pCOR_4$, $-(CH_2)_q(OR_6)_2$, $-(CH_2)_pOR_4$, $-(CH_2)_q-CH=CH-CN$, $-(CH_2)_q-CH=CH-CO_2H$,
 $-(CH_2)_p-CH=CH-CONHR_4R_5$, $-(CH_2)_pNHCOR_7$ or $-(CH_2)_pNR_8R_9$,

R_4 and R_5 are independently hydrogen or C_{1-6} alkyl;

R_6 is C_{1-6} alkyl;

5 R_7 is C_{1-7} alkyl, or optionally substituted aryl, heteroaryl, aryl C_{1-6} alkyl or heteroaryl C_{1-6} alkyl;

R_8 and R_9 are independently selected from hydrogen, C_{1-6} alkyl, aryl and aryl C_{1-6} alkyl;

p is 0-4;

q is 1-4;

10 one of X_1 and X_2 is N and the other is NR_{10} ; and

R_{10} is hydrogen, C_{1-6} alkyl, or C_{3-7} cycloalkyl;

provided that the compound is not:

- i) 2-[5-(2-methylphenyl)-2-propyl-1H-imidazol-4-yl]pyridine,
- ii) 2-[2-(1,1-dimethylethyl)-5-(4-methoxyphenyl)-1H-imidazol-4-yl]pyridine,
- 15 iii) 2-[2-(1,1-dimethylethyl)-5-phenyl-1H-imidazol-4-yl]pyridine,
- iv) 2-[5-(3,5-dichlorophenyl)-2-methyl-1H-imidazol-4-yl]pyridine,
- v) 2-[5-(3,5-dimethylphenyl)-2-methyl-1H-imidazol-4-yl]pyridine,
- vi) 2-[5-(3,5-dimethylphenyl)-2-ethyl-1H-imidazol-4-yl]pyridine,
- vii) 2-[5-(3,5-dimethylphenyl)-2-amino-1H-imidazol-4-yl]pyridine,
- 20 viii) 2-[5-(3,5-dimethylphenyl)-2-isopropyl-1H-imidazol-4-yl]pyridine,
- ix) 2-[5-(3,5-dimethylphenyl)-2-propyl-1H-imidazol-4-yl]pyridine, or
- x) 2-[5-(3,5-dimethylphenyl)-2-carboxamide-1H-imidazol-4-yl]pyridine.

As used herein, the double bond indicated by the dotted lines of formula (I), represent the possible tautomeric ring forms of the compounds falling within the scope of this invention, the
 25 double bond being to the unsubstituted nitrogen.

In a preferred group of compounds R_1 is optionally substituted naphthyl or phenyl. Preferably R_1 is phenyl optionally substituted with one or more substituents selected from the group consisting of halo, C_{1-6} alkoxy, C_{1-6} alkylthio, and phenyl; more preferably R_1 is phenyl optionally substituted with one or more substituents selected from the group consisting of halo,
 30 C_{1-6} alkoxy, C_{1-6} alkylthio, and cyano; or R_1 is phenyl or pyridyl (notably phenyl) fused with an aromatic or non-aromatic cyclic ring of 5-7 members wherein said cyclic ring optionally contains up to three heteroatoms, independently selected from N, O and S, and is optionally substituted by =O; for example R_1 represents benzo[1,3]dioxolyl, 2,3-dihydrobenzo[1,4]dioxinyl, benzoxazolyl, benzothiazolyl, quinoxalinyl, benzo[1,2,5]oxadiazolyl, benzo[1,2,5]thiadiazolyl,
 35 [1,2,4]triazolo[1,5-a]pyridyl, dihydrobenzofuranyl, benzo[1,4]oxazinyl-3-one or benzoxazolyl-2-one.

Preferably R_2 is other than hydrogen. When R_2 is other than hydrogen it is preferably positioned ortho to the nitrogen of the pyridyl ring.

Preferably R_3 is C_{1-6} alkyl or $(CH_2)_pNHCOR_7$ wherein R_7 is C_{1-7} alkyl, or optionally
 40 substituted aryl, heteroaryl, aryl C_{1-6} alkyl or heteroaryl C_{1-6} alkyl.

Preferably one of X_1 and X_2 is N and the other is NR_{10} , wherein R_{10} is hydrogen or C_{1-6} alkyl.

R_{10} is preferably hydrogen.

The compounds for use in the methods of the invention preferably have a molecular weight of less than 800, more preferably less than 600.

Specific compounds of the invention which may be mentioned include those described in the examples.

5 Suitable, pharmaceutically acceptable salts of the compounds of formula (I) include, but are not limited to, salts with inorganic acids such as hydrochloride, sulfate, phosphate, diphosphate, hydrobromide, and nitrate, or salts with an organic acid such as malate, maleate, fumarate, tartrate, succinate, citrate, acetate, lactate, methanesulfonate, p-toluenesulfonate, palmitate, salicylate, and stearate.

10 Some of the compounds of this invention may be crystallised or recrystallised from solvents such as aqueous and organic solvents. In such cases solvates may be formed. This invention includes within its scope stoichiometric solvates including hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation.

15 Certain of the compounds of formula (I) may exist in the form of optical isomers, e.g. diastereoisomers and mixtures of isomers in all ratios, e.g. racemic mixtures. The invention includes all such forms, in particular the pure isomeric forms. The different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses.

20 Since the compounds of formula (I) are intended for use in pharmaceutical compositions it will readily be understood that they are each preferably provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical
25 compositions; these less pure preparations of the compounds should contain at least 1%, more suitably at least 5% and preferably at least 10% of a compound of formula (I) or pharmaceutically acceptable derivative thereof.

30 The terms "C₁₋₆alkyl" and "C₁₋₇alkyl" as used herein whether on its own or as part of a larger group e.g. C₁₋₆alkoxy, means a straight or branched chain radical of 1 to 6 and 1 to 7 carbon atoms respectively, including, but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl.

C₁₋₆ haloalkyl groups may contain one or more halo atoms, a particular C₁₋₆ haloalkyl group that may be mentioned in CF₃.

35 The terms "halo" or "halogen" are used interchangeably herein to mean radicals derived from the elements chlorine, fluorine, iodine and bromine.

The term "C₃₋₇cycloalkyl" as used herein means cyclic radicals of 3 to 7 carbons, including but not limited to cyclopropyl, cyclopentyl and cyclohexyl.

40 The term "aryl" as used herein means 5- to 14-membered substituted or unsubstituted aromatic ring(s) or ring systems which may include bi- or tri-cyclic systems, including, but not limited to phenyl and naphthyl.

The term "ALK5 inhibitor" as used herein means a compound, other than inhibitory smads, e.g. smad6 and smad7, which selectively inhibits the ALK5 receptor preferentially over p38 or type II receptors.


The term "ALK5 mediated disease state" as used herein means any disease state which is mediated (or modulated) by ALK5, for example a disease which is modulated by the inhibition of the phosphorylation of smad 2/3 in the TGF-1 β signaling pathway.

The term "ulcers" as used herein includes, but is not limited to, diabetic ulcers, chronic ulcers, gastric ulcers, and duodenal ulcers.

The compounds of formula (I) can be prepared by art-recognized procedures from known or commercially available starting materials. If the starting materials are unavailable from a commercial source, their synthesis is described herein, or they can be prepared by procedures known in the art.


Specifically, compounds of formula (I) where one of X₁ and X₂ is NH may be prepared according to Scheme 1. The ketone may be oxidised to a diketone with HBr in DMSO. This diketone can then be condensed with a suitably substituted aldehyde or protected aldehyde derivative and ammonium acetate to give the imidazole according to the method outlined in WO 98/56788. Alternatively the ketone may be treated with sodium nitrite in HCl to afford an α -oximinoketone which can then be condensed with a suitably substituted aldehyde or protected aldehyde derivative and ammonium acetate to give the N-hydroxyimidazole. Treatment of this with triethylphosphite affords the imidazole according to the method outlined in US Pat. 5,656,644.

Scheme 1




Compounds of formula (I) where one of X₁ and X₂ is NH may also be prepared according to Scheme 2. A suitable bromide is coupled with trimethylsilylacetylene using palladium catalysis. The trimethylsilyl group can be removed by treatment with potassium carbonate and the terminal acetylene coupled with 6-bromo-2-methylpyridine again using palladium catalysis. The acetylene may then be oxidised to the diketone using palladium chloride in DMSO. Formation of the imidazole is then carried out with a suitable aldehyde as described in Scheme 1.

Scheme 2



Non-selective alkylation of the imidazole nitrogen (using one of the procedures outlined in N. J. Liverton et al; *J. Med. Chem.*, 1999, 42, 2180-2190) with a compound of formula L-R₁₀ wherein L is a leaving group, e.g. halo, sulfonate or triflate, will yield both isomers of the compounds where X₁ or X₂ is NR₁₀ in which R₁₀ is other than hydrogen, the isomers can be separated by chromatographic methods (Scheme 3).

Scheme 3




10

Compounds of formula (I) where R₃ is -CH₂NHCOR₇ may be prepared according to Scheme 4. The appropriate dione is condensed with (1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetaldehyde and ammonium acetate to form the imidazole. This product is treated with hydrazine to unmask the free amine which can then be coupled to an appropriate carboxylic acid using standard amide bond formation conditions.

15

Scheme 4



During the synthesis of the compounds of formula (I) labile functional groups in the intermediate compounds, e.g. hydroxy, carboxy and amino groups, may be protected. A comprehensive discussion of the ways in which various labile functional groups may be protected and methods for cleaving the resulting protected derivatives is given in for example *Protective Groups in Organic Chemistry*, T.W. Greene and P.G.M. Wuts, (Wiley-Interscience, New York, 2nd edition, 1991).

Further details for the preparation of compounds of formula (I) are found in the examples.

The compounds of formula (I) may be prepared singly or as compound libraries comprising at least 2, for example 5 to 1,000 compounds, and more preferably 10 to 100 compounds of formula (I). Libraries of compounds of formula (I) may be prepared by a combinatorial 'split and mix' approach or by multiple parallel synthesis using either solution phase or solid phase chemistry, by procedures known to those skilled in the art.

Thus according to a further aspect of the invention there is provided a compound library comprising at least 2 compounds of formula (I) or pharmaceutically acceptable salts thereof.

The invention further provides the use of a compound of formula (I), but without provisos i) to x), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease mediated by the ALK5 receptor in mammals.

The invention further provides a method of treatment of a disease mediated by the ALK5 receptor in mammals, comprising administering to a mammal in need of such treatment, a therapeutically effective amount of a compound of formula (I), but without provisos i) to x), or a pharmaceutically acceptable salt thereof.

ALK5-mediated disease states, include, but are not limited to, chronic renal disease, acute renal disease, wound healing, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers, ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, trophic conditions, atherosclerosis, any disease wherein fibrosis is a major

component, including, but not limited to peritoneal and sub-dermal adhesion, lung fibrosis and liver fibrosis, and restenosis.

By the term "treating" is meant either prophylactic or therapeutic therapy.

5 The invention further provides a method of inhibiting the TGF- β signaling pathway in mammals, for example, inhibiting the phosphorylation of smad2 or smad3 by the type I or activin-like kinase ALK5 receptor, which method comprises administering to a mammal in need of such treatment, a therapeutically effective amount of a compound of formula (I), but without provisos i) to x), or a pharmaceutically acceptable salt thereof.

10 The invention further provides the use of a compound of formula (I,) but without provisos i) to x), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for inhibiting the TGF- β signaling pathway in mammals.

The invention further provides a method of inhibiting matrix formation in mammals, for example, by inhibiting the phosphorylation of smad2 or smad3 by the type I or activin-like kinase ALK5 receptor, which method comprises administering to a mammal in need of such treatment, a therapeutically effective amount of a compound of formula (I), but without provisos i) to x), or a pharmaceutically acceptable salt thereof.

The invention further provides the use of a compound of formula (I), but without provisos i) to x), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for inhibiting matrix formation in mammals.

20 The compounds of formula (I) and pharmaceutically acceptable salts thereof, may be administered in conventional dosage forms prepared by combining a compound of formula (I), but without provisos i) to x), with standard pharmaceutical carriers or diluents according to conventional procedures well known in the art. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation.

25 According to a further aspect of the present invention there is provided a pharmaceutical composition comprising a compound of formula (I), but without provisos iv) to x), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.

30 The pharmaceutical compositions of the invention may be formulated for administration by any route, and include those in a form adapted for oral, topical or parenteral administration to mammals including humans.

The compositions may be formulated for administration by any route. The compositions may be in the form of tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions.

35 The topical formulations of the present invention may be presented as, for instance, ointments, creams or lotions, eye ointments and eye or ear drops, impregnated dressings and aerosols, and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration and emollients in ointments and creams.

40 The formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions. Such carriers may be present as from about 1% up to about 98% of the formulation. More usually they will form up to about 80% of the formulation.

Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives, such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl *p*-hydroxybenzoate or sorbic acid, and, if desired, conventional flavouring or colouring agents.

Suppositories will contain conventional suppository bases, e.g. cocoa-butter or other glyceride.

For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, water being preferred. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.

Advantageously, agents such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. The dry lyophilized powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use. Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilization cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

The compositions may contain from 0.1% by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration. Where the compositions comprise dosage units, each unit will preferably contain from 50-500 mg of the active ingredient. The dosage as employed for adult human treatment will preferably range from 100 to 3000 mg per day, for instance 1500 mg per day depending on the route and frequency of administration. Such a dosage corresponds to 1.5 to 50 mg/kg per day. Suitably the dosage is from 5 to 20 mg/kg per day.

It will be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a compound of formula (I), but without provisos i) to x), will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular mammal being treated, and that such optimums can be determined by

conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e. the number of doses of the compound of formula (I), but without provisos i) to x), given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.


5 No toxicological effects are indicated when a compound of formula (I), but without provisos i) to x), or a pharmaceutically acceptable salt thereof is administered in the above-mentioned dosage range.

All publications, including, but not limited to, patents and patent applications cited in this specification, are herein incorporated by reference as if each individual publication were
10 specifically and individually indicated to be incorporated by reference herein as though fully set forth.

The following examples are to be construed as merely illustrative and not a limitation on the scope of the invention in any way. In the Examples, mass spectra were performed using an Hitachi Perkin-Elmer RMU-6E with chemical ionization technique (CI) or a Micromass Platform II instrument with electrospray (ES) ionization technique.
15


EXAMPLES

20 **Description 1: 1-Benzo[1,3]dioxol-5-yl-2-(6-methyl-pyridin-2-yl)-ethane-1,2-dione (D1)**



1-Benzo[1,3]dioxol-5-yl-2-(6-methyl-pyridin-2-yl)-ethanone (3g, 1.7 mmol) (prepared according to the method described in U.S. Patent 3,940,486) was dissolved in dimethyl sulfoxide (50 ml) and heated to 60°C. Hydrogen bromide (11.9 ml of a 48% solution in water) was added dropwise
25 and the reaction stirred for 3 hours at 60 °C. The cooled reaction was poured into water (100 ml) and the pH adjusted to pH 8 with saturated sodium bicarbonate solution. The organic product was extracted into ethyl acetate (3 x 100 ml), dried (MgSO₄) and evaporated to dryness under reduced pressure. The title compound was isolated by silica gel column chromatography using ethyl acetate as eluent (2.35g, 74%). ¹H NMR (250 MHz, CDCl₃) δ: 2.51 (3H, s), 6.08 (2H, s),
30 6.86 (1H, d), 7.37 (1H, d), 7.42 (1H, dd), 7.46 (1H, d), 7.78 (1H, dt), 7.97 (1H, d); m/z (API⁺): 270 (MH⁺).


Description 2: 1-(6-Methyl-pyridin-2-yl)-2-quinoxalin-6-yl-ethane-1,2-dione 1-oxime (D2)



35


2-(6-Methyl-pyridin-2-yl)-1-quinoxalin-6-yl-ethanone (prepared according to the method described in U.S. Patent 3,940,486) (3.3g, 12.5mmol) was dissolved in a 5M hydrogen chloride solution and treated with a sodium nitrite (1.0g, 14.5mmol) and water (10ml) solution, whilst the reaction mixture was stirred vigorously. The reaction mixture was stirred at ambient temperature for one hour then quenched with ammonium chloride (40ml) and the pH adjusted to pH8 with 2M sodium hydroxide solution. The organic product was extracted into ethyl acetate (2x 100ml), dried (MgSO₄) and evaporated to dryness under reduced pressure. The title compound was isolated by silica gel chromatography using an equal ratio of ethyl acetate to petroleum ether as an eluent, (3.1g, 83%); m/z (API⁺): 293 (MH⁺).

Description 3: 1-(6-Methyl-pyridin-2-yl)-2-(4-methoxyphenyl)-ethane-1,2-dione (D3)




2-(6-Methyl-pyridin-2-yl)-1-(4-methoxyphenyl)-ethanone (1.7g) (prepared according to the method described in U.S. Patent 3,940,486) was dissolved in dimethyl sulfoxide (30ml) and heated to 70°C. 48% aqueous HBr (7ml) was added dropwise and heating continued for a further 3h. On cooling, the mixture was poured onto ice, neutralised with solid sodium bicarbonate and extracted with ethyl acetate. The organic extracts were dried (MgSO₄) and concentrated *in vacuo* to afford the title compound as a yellow oil; m/z (API⁺): 256 (MH⁺).

Description 4: 2-Amino-5-[2-*tert*-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]-phenol hydrochloride (D4)



Example 71 (2g, 6mmol) was dissolved in 2M aqueous HCl (50ml). After stirring at ambient temperature for 2h the solution was concentrated *in vacuo* to afford the title compound as a yellow solid. m/z (API⁺) 325.


Description 5: N'-(5-Bromo-2-aminopyridine)-N,N-dimethylformamidine (D5)




5-Bromo-2-aminopyridine (9.8 g, 56.6 mmol, 1 eq) was dissolved in dry DMF (20 ml) and dry dimethylformamide dimethylacetal (20 ml) under argon. The solution was refluxed at 130°C for 16 h, allowed to cool, and the solvents removed. The resultant residue was used in the next stage without purification. m/z [APCIMS]: 228./230. [M+H]⁺.

Description 6: 6-Bromo-[1,2,4] triazolo[1,5-a] pyridine (D6)


D5 (16.2 g, ~56.6 mmol, 1 eq) was dissolved in methanol (90 ml) and pyridine (10 ml) under




argon and cooled down to 0°C. To this was added, with stirring, hydroxylamine-O-sulfonic acid (7.3 g, 75.2 mmol, 1.3 eq) to form a purple suspension. This was allowed to reach room temperature and stirred for 16 h. After removing the solvents, the residue was suspended in aqueous sodium hydrogen carbonate (200 ml) and extracted with ethyl acetate (2x200 ml). The organic layer was then washed with water and brine (100 ml of each), dried (MgSO₄) and the solvent removed. Purification by flash chromatography on silica, eluting with a gradient solvent system of first 2:1 40-60°C petroleum ether:ethyl acetate to 1:1 40-60°C petroleum ether:ethyl acetate afforded the product as a pale yellow solid (5 g, 44.6%); ¹H NMR (250 MHz, CDCl₃) δ: 7.65 (1H, d), 7.69 (1H, d), 8.34 (1H, s), 8.77 (1H, s); m/z [APCIMS]: 198/200 [M+H]⁺.

Description 7: 6-Trimethylsilanylethynyl-[1,2,4] triazolo[1,5-a] pyridine (D7)


D6 (5 g, 25.26 mmol, 1 eq) was dissolved in THF (50 ml) and argon bubbled through the solution for five minutes. To this was added copper iodide (0.46 g, 2.53 mmol, 0.1 eq), dichlorobis(triphenylphosphine) palladium(0) (0.36 g, 0.51 mmol, 0.02 eq), and trimethylsilylacetylene (7.14 ml, 4.96 g, 50.52 mmol, 2 eq). Diisopropylamine (6.78 ml, 5.1 g, 50.52 mmol, 2 eq) was added dropwise to the solution and the resulting deep red suspension stirred under argon for 24 h. This was then filtered through celite, washing with an excess of ethyl acetate, and the solvents removed. The residue was then suspended in water (200 ml) and extracted with ethyl acetate (2x200 ml), and the organic layers combined, washed with water and brine (100 ml of each), dried (MgSO₄), and the solvent removed. Purification by flash chromatography over silica, eluting with 3:1 40-60°C petroleum ether: ethyl acetate afforded the product as a pale yellow solid (2.9 g, 53.3%). ¹H NMR (400 MHz, CDCl₃) δ: 0.28 (9H, s), 7.54 (1H, d), 7.69 (1H, d), 8.36 (1H, s), 8.72 (1H, s); m/z [APCIMS]: 216 [M+H]⁺.

Description 8: 6-Ethynyl-[1,2,4]triazolo[1,5-a] pyridine (D8)


D7 (2.9 g, 13.47 mmol, 1 eq) was dissolved in methanol and to this was added potassium carbonate (5.6 g, 40.4 mmol, 3 eq). The suspension was stirred for 2 h and the solvent removed. The residue was suspended in water (100 ml) and extracted with ethyl acetate (2x100 ml). The organic layers were then combined, washed with water and brine (50 ml of each), dried (MgSO₄), and the solvent removed to give a pale orange solid (1.8g, 95%) that was used in the next reaction without further purification. m/z [APCIMS]: 144.1 [M+H]⁺.

Description 9: 6-(6-Methylpyridin-2-ylethynyl)-[1,2,4] triazolo[1,5-a] pyridine (D9)

D8 (1.8 g, 12.56 mmol, 1 eq) was dissolved in anhydrous THF (50 ml) and TMEDA (50 ml) under argon. To this was added tetrakis(triphenylphosphine) palladium(0) (0.72 g, 0.63 mmol, 0.05 eq), copper iodide (0.24 g, 1.26 mmol, 0.1 eq) and 2-bromo-6-methylpyridine (4.32 g, 25.12 mmol, 2 eq). The mixture was then refluxed at 60°C for 5 h, allowed to cool, and the solvents removed. The residue was suspended in ethyl acetate and water (100 ml of each) and filtered through celite, washing with more ethyl acetate (100 ml). The aqueous layer was washed with further ethyl acetate (50 ml) and the organic layers combined. The organic solution was washed with water and brine (100 ml of each), dried (MgSO₄) and the solvent removed. Purification by flash chromatography over silica, eluting with ethyl acetate, afforded the title compound as a pale yellow solid (1 g, 34%). ¹H NMR (400 MHz, CDCl₃) δ: 2.61 (3H, s), 7.18 (1H, d), 7.40 (1H, d), 7.63 (1H, t), 7.68 (1H, d), 7.76 (1H, d), 8.40 (1H, s), 8.86 (1H, s); m/z [APCIMS]: 235 [M+H]⁺

Description 10: 1-(6-Methylpyridin-2-yl)-2-[1,2,4]triazolo[1,5-a]pyridin-6-yl-ethane-1,2-dione (D10)


A mixture of the acetylene (0.200 g, 0.854 mmol, 1.0 eq) and palladium(II) chloride (0.015 g, 0.085 mmol, 0.1 eq) in dry DMSO (4 ml) was heated at 140°C for 5 h then allowed to cool to room temperature. Water and ethyl acetate were added and the entire solution filtered through Kieselguhr. The layers were separated and the aqueous was extracted with more ethyl acetate. The combined organic phase was washed with water, brine and dried (MgSO₄). Concentration followed by column chromatography over silica, eluting with 50% Petrol-EtOAc – EtOAc afforded the title compound as a white solid, 0.090 g, 40%. ¹H NMR (400 MHz; CDCl₃) δ: 2.50 (3H, s), 7.41 (1H, d), 7.83 (1H, d), 7.88 (1H, d), 8.03 (1H, d), 8.13 (1H, d), 8.47 (1H, s), 9.11 (1H, s); m/z [ESMS]: 267.1 [M+H]⁺.

Description 11: 2-[2-tert-Butyl-5-(4-methoxy-3-nitrophenyl)-3H-imidazol-4-yl]-6-methylpyridine (D11)

Example 17 (2.88g, 9mmol) was dissolved in dichloromethane (19ml). Ammonium nitrate (1.15g, 14.3mmol) and trifluoroacetic anhydride (4.05ml, 28.7mmol) were added and the mixture


heated at reflux for 5h after which time more ammonium nitrate (575mg, 7.1mmol) and trifluoroacetic anhydride (2.20ml, 14.3mmol) were added. After a further 1h reflux the reaction mixture was cooled, diluted with more dichloromethane and washed with aq. sodium bicarbonate, water and brine. The organic phase was dried over sodium sulfate and evaporated to dryness to afford the title compound (3.3g). m/z [ESMS]: 367.2 $[M+H]^+$

Description 12: 2-[2-tert-Butyl-5-(4-hydroxy-3-nitrophenyl)-3H-imidazol-4-yl]-6-methylpyridine (D12)




D11 (1.07g, 2.9mmol) was dissolved in dry DMF (15ml). Lithium chloride (370mg, 8.8mmol) was added and the mixture heated at 160°C under argon overnight. On cooling, all volatiles were removed *in vacuo* and the residue partitioned between aq. ammonium chloride and ethyl acetate. The organic phase was dried over sodium sulfate and concentrated *in vacuo* to afford the title compound (1.0g). m/z [ESMS]: 353.2 $[M+H]^+$

Description 13: {4-[2-tert-Butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]-2-nitropneoxy}-acetic acid ethyl ester



D12 (770mg, 2.2mmol) was dissolved in dry DMF (10ml). Ethyl bromoacetate (486ul, 4.4mmol) and potassium carbonate (906mg, 6.6mmol) were added and the mixture stirred at 60°C under argon overnight. On cooling, the reaction mixture was diluted with water and extracted with ethyl acetate. The organic phase was dried ($MgSO_4$), concentrated *in vacuo* and the residue subjected to column chromatography eluting with 2:1 ethyl acetate : hexane to afford the title compound (465mg) m/z [ESMS]: 439.3 $[M+H]^+$.


Example 1: 2-[5-Benzo[1,3]dioxol-5-yl-2-(1,1-dimethoxy-methyl)-3H-imidazol-4-yl]-6-methyl-pyridine



D1 (2g, 7.4 mmol) was dissolved in *tert*-butyl methyl ether (20 ml) and treated with glyoxal 1,1-dimethyl acetal (2.6 ml of 45% solution in *tert*-butyl methyl ether). Ammonium acetate (1.49g)


in methanol (10 ml) was added and the reaction stirred at room temperature for 3 hours. The pH of the reaction was adjusted to pH 8 with saturated sodium carbonate solution. The reaction mixture was partitioned between dichloromethane (100 ml) and water (100 ml). The dichloromethane layer was separated, dried (MgSO_4) and evaporated to dryness under reduced pressure to yield the title compound (2.4g, 91%). ^1H NMR (250 MHz, CDCl_3) δ : 2.53 (3H, s), 3.43 (6H, s), 5.53 (1H, s), 5.99 (2H, s), 6.84 (1H, d, $J = 8$ Hz), 6.96 (1H, d, $J = 7$ Hz), 7.10-7.13 (2H, m), 7.32 (1H, d, $J = 8$ Hz), 7.45 (1H, t, $J = 8$ Hz), NH not observed; m/z (API^+): 354 (MH^+).

Example 2: 4-Benzo[1,3]dioxol-5-yl-5-(6-methyl-pyridin-2-yl)-1H-imidazole-2-carboxylic acid ethyl ester




Prepared from D1 (0.3g, 1.1 mmol) and ethyl glyoxylate (0.34 ml of a 50% solution in toluene) according to the procedure of Example 1. The title compound was isolated by silica gel column chromatography using a 1:9:190 ammonia: methanol:dichloromethane solution as eluent (0.089 g, 23%). ^1H NMR (250 MHz, CDCl_3) δ : 1.44 (3H, t, $J = 7$ Hz), 2.58 (3H, s), 4.48 (2H, q, $J = 7$ Hz), 6.01 (2H, s), 6.85 (1H, d, $J = 8$ Hz), 7.01 (1H, d, $J = 8$ Hz), 7.09-7.13 (2H, m), 7.33 (1H, d, $J = 8$ Hz), 7.45 (1H, t, $J = 8$ Hz), NH not observed; m/z (API^+): 352 (MH^+).

Example 3: 4-Benzo[1,3]dioxol-5-yl-5-(6-methyl-pyridin-2-yl)-1H-imidazole-2-carboxylic acid amide




Example 2 (0.2g, 0.57mmol) was dissolved in methanol (50 ml). Ammonia gas was bubbled through the solution (15 min) until saturation. The reaction flask was stoppered and left to stand at room temperature for 7 days before solvent removal under reduced pressure. The title compound was isolated by silica gel column chromatography using ethyl acetate as eluent (0.053 g, 29%). ^1H NMR (250 MHz, CDCl_3) δ : 2.55 (3H, s), 5.85 (1H, brs), 6.02 (3H, m), 6.88 (1H, d), 7.00-7.12 (3H, m), 7.28 (1H, d), 7.47 (1H, t), 11.25 (1H, brs); m/z (API^+): 323 (MH^+).

Example 4: 5-[4-Benzo[1,3]dioxol-5-yl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-pentanoic acid methyl ester




D1 (1.24g, 4.6 mmol) was dissolved in *tert*-butyl methyl ether (50 ml) and treated with adipic semialdehyde methyl ester, (1g, 6.9 mmol). Ammonium acetate (3.55g) in methanol (50 ml) was added and the reaction heated at reflux temperature for 18 hours. Solvent was removed from the cooled reaction under reduced pressure and the residue partitioned between sodium hydroxide (50 ml of a 2 M solution in water) and dichloromethane (100 ml). The dichloromethane layer was separated, dried (MgSO₄) and evaporated to dryness under reduced pressure. The title compound was isolated by silica gel column chromatography using a 1:9:190 ammonia: methanol:dichloromethane solution as eluent (1.15 g, 63%). ¹H NMR (250 MHz, CDCl₃) δ: 1.52-1.90 (4H, m), 2.30-2.40 (2H, m), 2.54 (3H, s), 2.80 (2H, brt, J = 7 Hz), 3.67 (3H, s), 5.99 (2H, s), 6.84 (1H, d, J = 9 Hz), 6.92 (1H, d, J = 8 Hz), 7.08 (1H, s), 7.11 (1H, d, J = 8 Hz), 7.29 (1H, d, J = 8 Hz), 7.40 (1H, t, J = 8 Hz), 10.17 (1H, brs); m/z (API⁺): 394 (MH⁺).

Example 5: 5-[4-Benzo[1,3]dioxol-5-yl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-pentanoic acid amide



Prepared from Example 4 (1g, 25 mmol) using the procedure of Example 3. 5-[4-Benzo[1,3]dioxol-5-yl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-pentanoic acid amide was isolated by silica gel column chromatography using a 1:9:190 ammonia: methanol:dichloromethane solution as eluent (0.32 g, 33%). ¹H NMR (250 MHz, CDCl₃) δ: 1.55-1.73 (4H, m), 2.19 (2H, t, J = 7 Hz), 2.46 (3H, s), 2.76 (2H, t, J = 7 Hz), 5.46 (1H, brs), 5.99 (2H, s), 6.32 (1H, brs), 6.83 (1H, d, J = 8 Hz), 6.95 (1H, d, J = 7 Hz), 7.07 (1H, s), 7.09 (1H, d, J = 8 Hz), 7.30 (1H, d, J = 8 Hz), 7.43 (1H, t, J = 8 Hz), NH not observed; m/z (API⁺): 379 (MH⁺).

Example 6: 4-Benzo[1,3]dioxol-5-yl-5-(6-methyl-pyridin-2-yl)-1H-imidazole-2-carboxaldehyde




Example 1 (0.3g, 0.85 mmol) was dissolved in hydrochloric acid (20 ml of a 2M solution in water) and heated at reflux temperature for 3 hours. The cooled solution was neutralised with saturated sodium bicarbonate and the product extracted into dichloromethane. The

dichloromethane solution was dried (MgSO₄) and the title compound isolated by solvent evaporation under reduced pressure (0.22 g, 84%). ¹H NMR (250 MHz, CDCl₃) δ: 2.53 (3H, s), 6.03 (2H, brs), 6.89 (1H, d, J = 8 Hz), 7.03-7.15 (4H, m), 7.37 (1H, d, J = 8 Hz), 7.50 (1H, t, J = 8 Hz), 9.76 (1H, s); m/z (API⁺): 308 (MH⁺).

5


Example 7: 3-[4-Benzo[1,3]dioxol-5-yl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-acrylonitrile



Example 6 (0.76g, 2.47 mmol) was dissolved in dichloromethane (100 ml). Cyanomethyl triphenyl phosphonium chloride (0.826g, 2.47 mmol) was added followed by diisopropyl ethylamine (0.85 ml, 48.7 mmol). The reaction mixture was stirred for 3 hours at room temperature then partitioned between water (200 ml) and dichloromethane (100 ml). The dichloromethane layer was separated, dried (MgSO₄) and evaporated to dryness under reduced pressure. 3-[4-Benzo[1,3]dioxol-5-yl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl] acrylonitrile was isolated by silica gel column chromatography using a 1:9:190 ammonia: methanol:dichloromethane solution as eluent (0.33 g, 41%). m/z (API⁺): 331 (MH⁺).

15

Example 8: (E)-3-[4-Benzo[1,3]dioxol-5-yl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-2-yl]-acrylamide




20

Example 7 (0.22g, 0.67 mmol) was dissolved in tert-butanol (50 ml) and treated with potassium hydroxide (0.112 g, 2 mmol). The reaction mixture was heated at reflux temperature for 18 hours before solvent removal under reduced pressure. The title compound was isolated by silica gel column chromatography using ethyl acetate as eluent (0.03g, 13%). ¹H NMR (250 MHz, CDCl₃) δ: 2.60 (3H, s), 5.68 (1H, brs), 5.90 (1H, d, J = 13 Hz), 5.99 (2H, s), 6.29 (1H, brs), 6.83 (1H, d, J = 8 Hz), 6.93 (1H, d, J = 13 Hz), 6.97 (1H, d, J = 8 Hz), 7.12 (1H, d, J = 8 Hz), 7.33 (1H, d, J = 8 Hz), 7.40-7.72 (3H, m); m/z (API⁺): 349 (MH⁺).

25


Example 9: 2-(5-Benzo[1,3]dioxol-5-yl-2-tert-butyl-3H-imidazol-4-yl)-6-methylpyridine

30




The title compound (280mg, 83%) was prepared from D1 (269mg, 1mmol) and pivalaldehyde (129mg, 1.5mmol), as described in Example 4, and isolated as a white foam, after chromatography on silica gel using ethyl acetate in 60-80⁰ petroleum ether as eluent: ¹H NMR (hydrochloride salt, 250MHz, CD₃OD) δ: 1.32 (9H, s), 2.48 (3H, s), 5.79 (2H, s), 6.68–6.78 (3H, m), 7.19 (1H, d, J = 8Hz), 7.33 (2H, d, J = 8Hz), 7.75 (1H, t, J = 8Hz); m/z (API⁺): 336 (MH⁺).

Example 10: 6-[2-Ethyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxaline




D2 (5g, 1.71mmol) was dissolved in acetic acid (50ml) and treated with ammonium acetate (2.64g, 34.3mmol) and propionaldehyde (0.12ml, 1.71mmol) and heated at 100°C for 30 minutes. The pH of the cooled reaction mixture was adjusted to pH8 at 0°C with a 2M sodium hydroxide solution. Organic product was extracted into dichloromethane (2x 100ml), dried (MgSO₄) and evaporated to dryness under reduced pressure, m/z (API⁺): 332 (MH⁺). Crude 2-ethyl-5-(6-methyl-pyridin-2-yl)-4-quinoxalin-6-yl-imidazol-1-ol (518mg, 1.56mmol) was dissolved in DMF, treated with triethylphosphite (0.83ml, 4.68mmol) and stirred at 130°C for five hours. The DMF was removed under reduced pressure and the product was partitioned between ethyl acetate (100ml) and water (100ml). Organic product was dried (MgSO₄) and evaporated to dryness under reduced pressure. The title compound was purified by silica gel column chromatography eluting with 5% methanol in dichloromethane (300mg, 56%); ¹H NMR (250 MHz, CDCl₃) δ: 1.42 (3H, t, J=7.5Hz), 2.56 (3H, s), 2.89 (2H, q, J=7.5Hz), 6.99 (1H, d, J=7.5Hz), 7.39-7.48 (2H, m), 8.12 (2H, s), 8.40 (1H, s), 8.82-8.85 (2H, m), NH not observed; m/z (API⁺): 316 (MH⁺).

Example 11: 6-[2-Ethyl-3-methyl-5-(6-methyl-pyridin-2-yl)-3H-imidazol-4-yl]-quinoxaline




Example 10 (100mg, 0.32mmol) was dissolved in dry tetrahydrofuran (50ml), cooled to 0°C and treated with sodium bis(trimethylsilyl)amide (0.35ml, 0.35mmol) and stirred at this temperature for 15 min before the addition of iodomethane (30μl, 0.48mmol). The reaction mixture was stirred at an ambient temperature for one hour, then product was diluted with water and extracted into dichloromethane (2x 100ml). The organic product was dried (MgSO₄) and evaporated to dryness under reduced pressure (55mg, 52%); ¹H NMR (250 MHz, CDCl₃) δ: 1.26-1.29 (3H, m), 2.15 (3H, s), 7.73 (2H, q, J=7.5Hz), 3.38 (3H, s), 6.74 (1H, d, J= 7.5Hz), 7.17-7.28 (2H, m), 7.63-7.68 (1H, m), 7.92-7.97 (2H, m), 8.72 (2H, s); m/z (API⁺): 330 (MH⁺).


Example 12: 6-[2-Isopropyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxaline

Prepared from D2 and isobutyraldehyde according to the procedure of Example 10. ¹H NMR (250 MHz, CDCl₃) δ: 1.38-1.41 (6H, m), 2.50 (3H, s), 3.18 (1H, m), 7.35 (1H, d, J=7.5Hz), 7.30-7.45 (2H, m), 8.13 (2H, s), 8.40 (1H, s), 8.81-8.84 (2H, m), NH not observed; m/z (API⁺): 330 (MH⁺).


Example 13: 6-[2-Isopropyl-3-methyl-5-(6-methyl-pyridin-2-yl)-3H-imidazol-4-yl]-quinoxaline



Prepared from Example 12 according to the procedure of Example 11. ¹H NMR (250 MHz, CDCl₃) δ: 1.31 (6H, d, J=7.5Hz), 2.12 (3H, s), 3.42 (3H, s), 3.02 (1H, m), 6.74 (1H, t, J=5Hz), 7.28-7.29 (2H, m), 7.65-7.69 (1H, m), 7.92-7.98 (2H, m), 8.73 (2H, s); m/z (API⁺): 334 (MH⁺).


Example 14 : 6-[2-Methyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-quinoxaline

Prepared from D2 and acetaldehyde according to the procedure of Example 10. ¹H NMR (250 MHz, CDCl₃) δ: 2.67 (3H, s), 2.81 (3H, s), 7.49 (2H, t, J=8.0Hz), 7.86-8.00 (2H, m), 8.24 (1H, d, J=8.75Hz), 8.37 (1H, s), 8.99 (2H, s), NH not observed; m/z (API⁺): 302 (MH⁺).

Example 15: 6-[2,3-Dimethyl-5-(6-methyl-pyridin-2-yl)-3H-imidazol-4-yl]-quinoxaline


Prepared from Example 14 according to the procedure of Example 11. ^1H NMR (250 MHz, CDCl_3) δ : 2.32 (3H, s), 2.57 (3H, s), 3.52 (3H, s), 6.89 (1H, d, $J=7.5\text{Hz}$), 7.28 (1H, s), 7.36-7.45 (1H, m), 7.79-7.83 (1H, m), 8.11 (2H, d, $J=10\text{Hz}$), 8.89 (2H, s); m/z (API^+): 316 (MH^+).

5 **Example 16: 6-[2-*tert*-Butyl-5-(6-methyl-pyridin-2-yl)-1*H*-imidazol-4-yl]-quinoxaline**




Prepared from D2 and pivalaldehyde according to the procedure of Example 10. ^1H NMR (250MHz; CDCl_3) δ : 1.43 (9H, s), 2.78 (3H, s), 6.97 (1H, d, $J=7.5\text{Hz}$), 7.31 (1H, s), 7.42 (1H, t, $J=7.5\text{Hz}$), 8.09 – 8.18 (2H, m), 8.40 (1H, s), 8.82 – 8.87 (2H, m), NH not observed; m/z [ESMS]:
10 344.2 [$\text{M}+\text{H}$] $^+$

Example 17: 2-[*tert*-Butyl-5-(4-methoxyphenyl)-3*H*-imidazol-4-yl]-6-methylpyridine



Prepared from D3 and pivalaldehyde according to the procedure of Example 4. ^1H NMR (250 MHz, CDCl_3) δ : 1.41 (9H, s), 2.42 (3H, s), 3.84 (3H, s), 6.91 (3H, m), 7.17 (1H, d), 7.42 (1H, t), 7.51 (2H, m), NH not observed; m/z (API^+) 322 (MH^+).


Example 18: 2-[Methyl-5-(4-methoxyphenyl)-3*H*-imidazol-4-yl]-6-methylpyridine



20 D3 (250mg, 0.1mmol) was dissolved in *tert*-butyl methylether (20ml) and methanol (5ml). Acetaldehyde (2ml) was added and the mixture heated at reflux overnight. Further portions of acetaldehyde (3x1ml) were added at 2, 4 and 6h. On cooling the reaction mixture was diluted with ethyl acetate and washed sequentially with *aq.* sodium bicarbonate, water and brine. The
25 organic phase was dried (Na_2SO_4) and concentrated *in vacuo* to afford a brown oil which was subjected to dry flash chromatography on silica gel eluting with 5% methanol in dichloromethane to afford a pale yellow oil. ^1H NMR (250 MHz, CDCl_3) δ : 2.43 (3H, s), 2.51 (3H, s), 3.84 (3H, s), 6.92 (3H, m), 7.27 (1H, d), 7.38 (1H, t), 7.52 (2H, m), NH not observed; m/z (API^+) 322 (MH^+).


30

Example 19: 7-[2-*tert*-Butyl-5-(6-methylpyridin-2-yl)-1*H*-imidazol-4-yl]-4*H*-benzo[1,4]oxazin-3-one




To a solution of D4 (30 mg, 0.084 mmol, 1.0 eq) in dry DMF (0.5 ml) under argon at room temperature was added chloroacetyl chloride (10 mg, 0.092 mmol, 7.5 μ l, 1.1 eq). Potassium carbonate (46 mg, 0.334 mmol, 4.0 eq) was added portionwise and the resultant mixture stirred for 16 h at room temperature. The reaction mixture was diluted with water (10 ml) and extracted with EtOAc (2 x 10 ml). The organic solution was washed with water and brine (20 ml of each) then dried (MgSO₄) and the solvents removed. Purification by flash column chromatography over silica, eluting with 9 : 1 CH₂Cl₂ : MeOH + 1% Et₃N afforded the title compound as an off white solid. ¹H NMR (400 MHz; DMSO-*d*₆) δ : 1.52 (9H, s), 2.67 (3H, s), 4.63 (2H, s), 6.98 (1H, d), 7.11 (1H, d), 7.22 (1H, s), 7.28 (1H, d), 7.37 (1H, d), 7.80 (1H, t), 10.98 (1H, br.s), NH not observed; *m/z* [ESMS]: 363.2 [M+H]⁺.

Example 20: 6-[2-*tert*-Butyl-5-(6-methylpyridin-2-yl)-1*H*-imidazol-4-yl]-3*H*-benzoxazol-2-one




To a stirred solution of D4 (40 mg, 0.111 mmol, 1.0 eq) and 1,1'-carbonyldiimidazole (20 mg, 0.123 mmol, 1.1 eq) in anhydrous DMF (1.1 ml) under argon at room temperature was added dropwise triethylamine (56 mg, 77 μ l, 5.0 eq). The resultant mixture was stirred at room temperature for 16 h then diluted with water (10 ml). The mixture was extracted with EtOAc (2 x 10 ml) and the organic solution washed with water and brine (20 ml of each) then dried (MgSO₄) and the solvents removed. Purification by flash column chromatography over silica, eluting with 25 : 1 CH₂Cl₂ : MeOH + 1% Et₃N afforded the title compound as an off white solid. ¹H NMR (250 MHz; CD₃OD) δ : 1.34 (9H, s), 2.41 (3H, s), 6.94 (1H, d), 7.11-7.07 (2H, m), 7.14 (1H, d), 7.18 (1H, s), 7.46 (1H, t), NHs not observed; *m/z* [ESMS]: 349.2 [M+H]⁺.

Example 21: 7-[2-*tert*-Butyl-5-(6-methylpyridin-2-yl)-1*H*-imidazol-4-yl]-3,4-dihydro-2*H*-benzo[1,4]oxazine



To a solution of Example 19 (19 mg, 0.052 mmol, 1.0 eq) in anhydrous THF (0.75 ml) under argon at room temperature was added dropwise LiAlH_4 solution (262 μl 1M solution in ether, 0.262 mmol, 5.0 eq). An effervescence was observed as hydrogen was evolved and the resultant orange mixture was stirred at room temperature for 5 h. Methanol was added (1 ml) and the reaction mixture stirred vigorously with saturated aqueous potassium sodium tartrate solution (30 ml) and EtOAc (30 ml) for 2 h. The layers were separated and the organic washed with water, and brine (30 ml of each) and dried (MgSO_4) and the solvents removed. Purification by flash column chromatography over silica, eluting with 9 : 1 CH_2Cl_2 : MeOH + 1% Et_3N afforded the title compound as an off white solid. ^1H NMR (250 MHz; CD_3OD) δ : 1.33 (9H, s), 2.44 (3H, s), 3.24 (2H, t), 4.07 (2H, t), 6.48 (1H, d), 6.68-6.64 (2H, m), 6.99 (1H, d), 7.09 (1H, d), 7.44 (1H, t), NHs not observed; m/z [ESMS]: 349.3 $[\text{M}+\text{H}]^+$.


Example 22: 2-[4-Benzo[1,3]dioxol-5-yl-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl]-methylamine



2-[4-Benzo[1,3]dioxol-5-yl-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl-methyl]-isindole-1,3-dione (3g), prepared from D1 and (1,3-dioxo-1,3-dihydro-isindol-2-yl)-acetaldehyde according to the procedure of Example 4, was dissolved in ethanol (200ml) and treated with hydrazine monohydrate (2ml). The reaction was heated at reflux for 4h, cooled, treated with acetone to quench excess hydrazine, and evaporated to dryness. The residue was then taken up in 2M hydrochloric acid, neutralised to pH 8 and extracted with dichloromethane. The combined organic layers were dried (MgSO_4), concentrated *in vacuo* and the residue subjected to dry flash chromatography on silica gel eluting with 90:9:1 dichloromethane, methanol, 0.88 ammonia to afford the title compound as an off white solid. ^1H NMR (250 MHz, CDCl_3) δ : 2.53 (3H, s), 4.05 (2H, s), 5.99 (2H, s), 6.83 (1H, d, $J = 6\text{Hz}$), 6.94 (1H, d, $J = 7\text{Hz}$), 7.08 (2H, m), 7.28 (1H, d, $J = 10\text{Hz}$), 7.41 (1H, d, $J = 7\text{Hz}$) NHs not observed; m/z (API+) 309.


Examples 23-70

Stock solutions of 1-hydroxybenzotriazole (700mg in 35ml) and Example 22 (1.078g in 35ml) were made up in DMF. Excess N-cyclohexylcarbodiimide, N-methyl polystyrene was added to a Robbins FlexChem reaction block via a shallow 96 well plate. 1-Hydroxybenzotriazole solution (3ml, 0.075mmol) was added to to each well followed by the solution of Example 22 (0.5ml, 0.05mmol). Acids (0.1mmol in 0.5ml DMF) were then added to individual wells, the block sealed and shaken for 60h. Resin bound isocyanate was then added and shaking continued for 18h followed by addition of Amberlyte IRA-93 and a further 18h shaking. Individual wells were then filtered and concentrated *in vacuo* to afford the coupled products.




Example	R	m/z (API+)	Example	R	m/z (AP I+)
23		471	47		514
24	4-methoxybenzyl	456	48	3-thiophenyl	419
25	4-dimethylaminobenzyl	471	49	2-methoxy-4-thiomethylphenyl	490
26	n-propyl	379	50	6-methyl-pyridin-3-yl	428
27	n-heptyl	436	51	6-chloro-pyridin-3-yl	449
28	4-nitrobenzyl	472	52	2,6-dimethoxy pyridin-3-yl	474
29	cinnamyl	439	53	2-naphthyl	464
30		500	54		490
31	-CH ₂ OPh	443	55	3-bromophenyl	492
32	cyclohexyl	419	56	2-quinolyl	464
	-(CH ₂) ₃ -Ph	456	57	2-pyrazinyl	415
34	benzyl	427	58	4-pyridyl	414
35		478	59		466
36		504	60		417
37		518	61		433
38	3-chlorobenzyl	462	62		429
39	4-fluorobenzyl	445	63	-(CH ₂) ₂ -C(O)Ph	469
40		467	64		469
41	4-phenoxyphenyl	506	65	-CH ₂ SPh	460
42	4-benzoylphenyl	518	66	4-methoxyphenyl	443
43	4-acetylphenyl	455	67	benzofuran-2-yl	453
44	3-nitrophenyl	458	68	4-trifluomethylphenyl	481
45	4-nitrophenyl	458	69	piperonyl	457
46	3,5-dichlorophenyl	482	70	4-n-pentyloxyphenyl	500

Example 71: 6-[2-tert-Butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-benzoxazole




Prepared from 1-benzoxalol-6-yl-2-(6-methylpyridin-2-yl)-ethane-1,2-dione 2-oxime (prepared via the oximinoketone route described in Scheme 1) and pivalaldehyde according to the method of Example 10. ¹H NMR (250 MHz, CDCl₃) δ: 1.40 (9H, s), 2.40 (3H, s), 6.94 (1H, d, J = 8 Hz), 7.19 (1H, d, J = 8 Hz), 7.62 (1H, t, J = 8 Hz), 7.65 (1H, dd, J = 8 and 1 Hz), 7.89 (1H, s), 8.10 (1H, s), 11.06 (1H, br.s), NH not observed; m/z [API]: 333.1 [M+H]⁺

Example 72: 6-[2-*tert*-Butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]-[1,2,4]triazolo[1,5-a]pyridine




Prepared from 1-(6-methylpyridin-2-yl)-2-[1,2,4]triazolo[1,5-a]pyridin-6-yl-ethane-1,2-dione (D10) and pivaldehyde according to the method of Example 4. ¹H NMR (250 MHz; CDCl₃) δ: 1.36 (9H, s), 2.35 (3H, s), 7.02 (1H, d), 7.17 (1H, d), 7.51 (1H, t), 7.78 (2H, s), 8.38 (1H, s), 8.91 (1H, s), NH not observed; m/z [CIMS]: 333 [M+H]⁺.

Example 73: 6-[2-*tert*-Butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]-1H-benzimidazole




To a stirred solution of a mixture of 1- and 3-benzyl-5-[2-*tert*-butyl-5-(6-methylpyridin-2-yl)-1H-benzimidazole (prepared via the diketone route described in Scheme 1) (1.53 g, 3.63 mmol, 1.0 eq) in anhydrous 1,4-dioxane (70 ml) under argon at room temperature was added dropwise a solution of sodium naphthalenide (91 ml 0.4M in THF, 36.3 mmol, 10.0 eq). The resultant brown mixture was stirred for a further 16 h under argon then open to the air for 20 min before partitioning between water and ethyl acetate. The organic phase was washed with water, brine, dried (MgSO₄) and concentrated to a yellow solid. The solid was triturated with 40-60 petrol to remove most of the naphthalene then purified by flash column chromatography, eluting with EtOAc → 20% MeOH-EtOAc. The title compound was obtained as a yellow solid (0.780 g, 65%). ¹H NMR (400 MHz; CDCl₃) δ: 1.49 (9H, s), 2.52 (3H, s), 6.90 (1H, d), 7.23 (1H, d), 7.32 (1H, t), 7.41 (1H, d), 7.62 (1H, br.s), 7.87 (1H, s), 7.98 (1H, br.s), NHs not observed; m/z [ESMS]: 332.2 [M+H]⁺.

Example 74: 6-[2-Isopropyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]-[1,2,4]-triazolo-[1,5-a]pyridine




5 Prepared from D10 and isobutyraldehyde according to the method of Example 4. ^1H NMR (250 MHz; CDCl_3) δ : 1.31 (6H, d), 2.42 (3H, s), 3.12 (1H, h), 7.01 (1H, d), 7.22 (1H, d), 7.49 (1H, t), 7.76 (1H, d), 7.81 (1H, d), 8.36 (1H, s), 8.91 (1H, s), NH not observed; m/z [ESMS]: 319 $[\text{M}+\text{H}]^+$.

10 **Example 75: 5-[2-tert-Butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]-benzo[1,2,5]oxadiazole**




Prepared from 1-benzo[1,2,5]oxadiazol-5-yl-2-(6-methylpyridin-2-yl)-ethane-1,2-dione 2-oxime (prepared according to the route outlined in Scheme 1) and pivalaldehyde according to the method of Example 10. ^1H NMR (250 MHz, CDCl_3) δ : 1.59 (9H, s), 2.52 (3H, s), 7.02 (1H, d), 7.27 (1H, d), 7.48 (1H, t), 7.76 (1H, dd), 7.82 (1H, dd), 8.11 (1H, t), NH not observed; m/z [APCIMS]: 334.2 $[\text{M}+\text{H}]^+$, 332.1 $[\text{M}-\text{H}]^-$.

20 **Example 76: 5-[2-Methyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]-benzo[1,2,5]oxadiazole**




Prepared from 1-benzo[1,2,5]oxadiazol-5-yl-2-(6-methylpyridin-2-yl)-ethane-1,2-dione 2-oxime (prepared according to the route outlined in Scheme 1) and acetaldehyde according to the method of Example 10. ^1H NMR (250 MHz, CDCl_3) δ : 2.54 (3H, s), 2.58 (3H, s), 7.04 (1H, d), 7.30 (1H, d), 7.49 (1H, t), 7.76 (1H, dd), 7.83 (1H, dd), 8.11 (1H, s), NH not observed; m/z [APCIMS]: 292.1 $[\text{M}+\text{H}]^+$, 290.1 $[\text{M}-\text{H}]^-$.

Example 77: 5-[2-Isopropyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]-benzo[1,2,5]oxadiazole




Prepared from 1-benzo[1,2,5]oxadiazol-5-yl-2-(6-methylpyridin-2-yl)-ethane-1,2-dione 2-oxime (prepared according to the route outlined in Scheme 1) and isobutyraldehyde according to the method of Example 10. ¹H NMR (250MHz, CDCl₃) δ: 1.40 (6H, s), 2.54 (3H, s), 3.12 (1H, h)
 5 7.04 (1H, d), 7.28 (1H, d), 7.49 (1H, t), 7.76 (1H, dd), 7.83 (1H, dd), 8.11 (1H, t), NH not observed; m/z [APCIMS]: 320.2 [M+H]⁺, 318.1 [M-H]⁻.

Example 78: 2-[2-tert-Butyl-5-(2,3-dihydrobenzofuran-5-yl)-3H-imidazol-4-yl]-6-methylpyridine




10 Prepared from 1-(2,3-dihydrobenzofuran-5-yl)-2-(6-methylpyridin-2-yl)-ethane-1,2-dione (prepared according to the route outlined in Scheme 1) and pivalaldehyde according to the method of Example 4. ¹H NMR (400 MHz, CDCl₃) δ: 1.43 (9H, s), 2.48 (3H, s), 3.22 (2H, t),
 15 4.60 (2H, t), 6.77 (1H, d), 6.88 (1H, d), 7.24 (1H, d), 7.33 (2H, m), 7.48 (1H, s), NH not observed; m/z [APCIMS]: 334.3 [M+H]⁺, 332.2 [M-H]⁻.

Example 79: 5-[2-Ethyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-benzothiazole




20 Prepared from 1-benzothiazol-5-yl-2-(6-methylpyridin-2-yl)-ethane-1,2-dione 2-oxime (prepared according to the route outlined in Scheme 1) according to the method of Example 10. ¹H NMR (250 MHz, CDCl₃) δ: 1.34 (3H, t), 2.51 (3H, s), 2.83 (2H, q), 6.98 (1H, d), 7.24-7.40 (2H, m),
 25 7.77 (1H, dd), 7.99 (1H, d), 8.38 (1H, d), 9.01 (1H, s), NH not observed; m/z (API⁺): 321.1 (MH⁺).

Example 80: 5-[2-tert-Butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-benzo[1,2,5]thiadiazole




Prepared from 1-benzo[1,2,5]thiadiazol-5-yl-2-(6-methylpyridine-2-yl)-ethane-1,2-dione oxime (prepared according to the route outlined in Scheme 1) and pivalaldehyde according to the method of Example 4. ¹H NMR (250 MHz, CDCl₃) δ: 1.21 (9H, s), 2.24 (3H, s), 6.91 (1H, d), 7.21 (1H, d), 7.39 (1H, t), 7.85-7.90 (2H, m), 8.20 (1H, s), 11.80 (1H, br. s); m/z (API⁺): 350.2 (MH⁺).

Example 81: 6-[2-tert-Butyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-benzothiazole




Prepared from 1-benzothiazol-5-yl-2-(6-methylpyridin-2-yl)-ethane-1,2-dione 2-oxime (prepared according to the route outlined in Scheme 1) and pivalaldehyde according to the method of Example 10. ¹H NMR (250 MHz, CDCl₃) δ: 1.39 (9H, s), 2.38 (3H, s), 6.94 (1H, d, J = 7.5 Hz), 7.20 (1H, d, J = 7.5 Hz), 7.40 (1H, t, J = 7.5 Hz), 7.75 (1H, dd, J = 8.5 and 1.5 Hz), 8.10 (1H, d, J = 8.5 Hz), 8.30 (1H, d, J = 1.5 Hz), 9.00 (1H, s), 11.29 (1, br.s); m/z (API⁺): 349.2 (MH⁺).

Example 82: 6-[2-Methyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-benzothiazole



Prepared from 1-benzothiazol-5-yl-2-(6-methylpyridin-2-yl)-ethane-1,2-dione 2-oxime (prepared according to the route outlined in Scheme 1) and acetaldehyde according to the method of Example 10. ¹H NMR (250 MHz, CDCl₃) δ: 2.50 (3H, s), 2.54 (3H, s), 6.97 (1H, d), 7.25-7.28 (1H, m), 7.40 (1H, t), 7.77 (1H, dd), 8.12 (1H, d), 8.27 (1H, d), 9.01 (1H, s), NH not observed; m/z (API⁺): 307.1 (MH⁺).


Example 83: 5-[2-Isopropyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-benzo[1,2,5]thiadiazole



Prepared from 1-benzo[1,2,5]thiadiazol-5-yl-2-(6-methylpyridine-2-yl)-ethane-1,2-dione 2-oxime (prepared according to the route outlined in Scheme 1) and isobutyraldehyde. ^1H NMR (250 MHz, CDCl_3) δ : 1.29 (6H, d), 2.37 (3H, s), 3.06-3.23 (1H, m), 7.00 (1H, d), 7.31 (1H, d), 7.47 (1H, t), 7.92-8.04 (2H, m), 8.27 (1H, s), 11.89 (1H, br.s); m/z (API^+): 335.43 (MH^+).

5


Example 84: 6-[2-Methyl-5-(6-methyl-pyridin-2-yl)-1H-imidazol-4-yl]-benzo[1,2,3]thiadiazole



Prepared from 1-benzo[1,2,3]thiadiazol-6-yl-2-(6-methyl-pyridin-2-yl)-ethane-1,2-dione 2-oxime (prepared according to the route outlined in Scheme 1) and acetaldehyde. ^1H NMR (250 MHz, CDCl_3) δ : 2.54 (3H, s), 2.57 (3H, s), 7.02 (1H, d, $J = 8$ Hz), 7.24-7.65 (1 H, m), 7.47 (1H, t, $J = 8$ Hz), 7.91 (1H, dd, $J = 8.5$ and 1 Hz), 8.41 (1H, d, $J = 1$ Hz), 8.59 (1H, d, $J = 8.5$ Hz), NH not observed; m/z (API^+): 308.1 (MH^+).





15 Examples 85-120

Prepared from 2-[5-(6-methylpyridin-2-yl)-4-quinoxalin-6-yl-1H-imidazol-2-yl]-methylamine according to the method of Examples 23-70.



20


Example	R	m/z (API^+)	Example	R	m/z (API^+)
85		425	103	4-methoxyphenyl	451
86	benzyl	435	104	4-acetylphenyl	463
87	3-chlorobenzyl	470	105	4-trifluorophenyl	489
88	4-fluorobenzyl	453	106	2-methoxy-4-methylsulfanylphenyl	497
89	4-methoxybenzyl	465	107	4-n-pentyloxyphenyl	507
90	-(CH_2) ₃ -Ph	463	108	3-thiophenyl	427
91	4-nitrobenzyl	480	109	1-methylindol-2-yl	474
92	4-dimethylaminobenzyl	478	110	benzofuran-2-yl	461
93	cyclohexyl	427	111	pyrazin-2-yl	423
94	n-propyl	387	112	6-chloro-pyridin-3-yl	456
95	- CH_2SPh	467	113	6-methyl-pyridin-3-yl	436



96	cinnamyl	447	114		522
97	n-heptyl	443	115	2-quinolyl	521
98		441	116	3-methylbenzyl	472
99		479	117	4-t-butylphenyl	449
100		507	118	4-ethylphenyl	477
101	3-bromophenyl	501	119	2,3-dimethylphenyl	449
102	4-phenoxyphenyl	513	120	2,6-dimethylphenyl	449




Examples 121-165

Prepared from 2-[4-(4-methoxyphenyl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl]-methylamine according to the method of Examples 23-70.


5



Example	R	m/z (API ⁺)	Example	R	m/z (API ⁺)
121		403	144	4-trifluorophenyl	467
122	benzyl	413	145	naphthyl	449
123	3-chlorobenzyl	447	146	piperonyl	443
124	4-fluorobenzyl	431	147	3-nitrophenyl	444
125	4-methoxybenzyl	443	148	4-nitrophenyl	444
126	-(CH ₂) ₃ -Ph	441	149	2-methoxy-4-methylsulfanylphenyl	475
127	4-nitrobenzyl	458	150	4-n-pentyloxyphenyl	485
128	4-dimethylaminobenzyl	456	151	3-thiophenyl	405
129	cyclohexyl	405	152	1-methylindol-2-yl	452
130	n-propyl	365	153	benzofuran-2-yl	439
131	-CH ₂ SPh	445	154	pyrazin-2-yl	401
132	cinnamyl	425	155	6-chloro-pyridin-3-yl	434
133	n-heptyl	421		pyridin-4-yl	400
			156		
134		419	157	benzothiophen-2-yl	455
135	indol-3-yl	452	158	2,6-dimethoxypyridin-3-yl	460


136		457	159		499
137		485	160	2-quinolyl	450
138	3-bromophenyl	478			
139	3,5-dichlorophenyl	468	161	3-methylbenzyl	427
140	4-phenoxyphenyl	491	162	4- <i>t</i> -butylphenyl	455
141	4-methoxyphenyl	429	163	4-ethylphenyl	427
142	4-phenylphenyl	475	164	2,3-dimethylphenyl	427
143	4-acetylphenyl	441	165	2,6-dimethylphenyl	427

Example 166: 6-[2-*tert*-Butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]-4H-benzo[1,4]oxazin-3-one




- 5 D13 (133mg, 0.3mmol) was dissolved in acetic acid (2ml). Iron powder (339mg, 6mmol) was added and the mixture stirred vigorously at 70°C for 2h. On cooling, the mixture was filtered through celite, washing with ethyl acetate. The solution was then evaporated to dryness and the residue partitioned between aq. sodium bicarbonate and ethyl acetate. The organic phase was dried over sodium sulfate, evaporated to dryness and the residue subjected to chromatography on silica gel eluting with 5% methanol in ethyl acetate to afford the title compound (73mg). ¹H NMR (250 MHz; DMSO-*d*₆) Spectrum very broad due to restricted rotation on NMR timescale δ: 1.37 (9H, s), 2.49 (3H, s), 4.57 (2H, s), 6.80-7.31 and 7.63-7.57 (6H, m), 10.70 (1H, br.s), 11.80 (1H, br.s); m/z [ESMS]: 363.3 [M+H]⁺.

- 15 **Example 167: 6-[2-*tert*-Butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]-4H-benzo[1,4]oxazine**



- Prepared from Example 166 according to the procedure of Example 21. ¹H NMR (250 MHz; DMSO-*d*₆) Spectrum broad due to restricted rotation on NMR timescale δ: 1.33 (9H, s), 2.43 (3H, s), 3.25 (2H, t), 4.10 (2H, t), 6.80-6.45 (3H, m), 7.00 (1H, d), 7.09 (1H, d), 7.50-7.41 (1H, m), NHs not observed; m/z [ESMS]: 349.3 [M+H]⁺.

Example 168: 6-[2-*tert*-Butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]-quinoline



Prepared from 1-(6-methyl-pyridin-2-yl)-2-quinolin-6-yl-ethane-1,2-dione 1-oxime (prepared according to the route outlined in Scheme 1). ^1H NMR (250 MHz, CDCl_3) δ : 1.41 (9H, s), 2.37 (3H, s), 6.93 (1H, d, $J = 7.5$ Hz), 7.21 (1H, d, $J = 8$ Hz), 7.38-7.41 (2H, m), 7.92 (1H, dd, $J = 9$ and 2 Hz), 8.08 (1H, d, $J = 9$ Hz), 8.16-8.18 (2H, m), 8.88-8.91 (1H, m), 11.41 (1H, brs); m/z (API $^+$): 343.3 (MH $^+$).

Biological Data

The biological activity of the compounds of the invention may be assessed using the following assays:

Method for evaluating ALK5 kinase phosphorylation of smad3

Basic Flash-Plates (NEN Life Sciences) were coated by pipetting 100 micro liter of 0.1 molar sodium bicarbonate (pH 7.6), containing 150 nanograms of the fusion protein glutathion-S-transferase-smad3/100 micro liter of coating buffer. Plates were covered and incubated at room temperature for 10-24 hours. Then the plates were washed 2 times with 200 micro liter of coating buffer (0.1 molar sodium bicarbonate) and allowed to air dry for 2-4 hours.

For the phosphorylation reaction each well received 90 microliter containing 50 millimolar HEPES buffer (pH 7.4); 5 millimolar MgCl_2 ; 1 millimolar CaCl_2 ; 1 millimolar dithiothreitol; 100 micromolar guanosine triphosphate; 0.5 micro Ci/well gamma ^{33}P -adenosine triphosphate (NEN Life Sciences) and 400 nanograms of a fusion protein of glutathion-S-transferase at the N-terminal end of the kinase domain of ALK5 (GST-ALK5). Background counts were measured by not adding any GST-ALK5. Inhibitors of ALK5 were evaluated by determining the activity of the enzyme in the presence of various compounds. Plates were incubated for 3 hours at 30°C. After incubation the assay buffer was removed by aspiration and the wells were washed 3 times with 200 microliter cold 10 millimolar sodium pyrophosphate in phosphate buffered saline. The last wash was aspirated and blotted plate dry. Plate was then counted on a Packard TopCount.

Fluorescence Anisotropy Kinase Binding Assay

The kinase enzyme, fluorescent ligand and a variable concentration of test compound are incubated together to reach thermodynamic equilibrium under conditions such that in the absence of test compound the fluorescent ligand is significantly (>50%) enzyme bound and in the presence of a sufficient concentration (>10x K_i) of a potent inhibitor the anisotropy of the unbound fluorescent ligand is measurably different from the bound value.

The concentration of kinase enzyme should preferably be $\geq 1 \times K_f$. The concentration of fluorescent ligand required will depend on the instrumentation used, and the fluorescent and physicochemical properties. The concentration used must be lower than the concentration of kinase enzyme, and preferably less than half the kinase enzyme concentration. A typical protocol is:

All components dissolved in Buffer of final composition 50 mM HEPES, pH 7.5, 1 mM CHAPS, 1 mM DTT, 10 mM MgCl₂ 2.5% DMSO.

ALK5 Enzyme concentration: 4 nM

Fluorescent ligand concentration: 1 nM

5 Test compound concentration: 0.1 nM - 100 uM


Components incubated in 10 ul final volume in LJI HE 384 type B black microtitre plate until equilibrium reached (5-30 mins)

Fluorescence anisotropy read in LJI Acquest.

Definitions: K_i = dissociation constant for inhibitor binding

10 K_f = dissociation constant for fluorescent ligand binding

The fluorescent ligand is the following compound:



which is derived from 5-[2-(4-aminomethylphenyl)-5-pyridin-4-yl-1H-imidazol-4-yl]-2-chlorophenol and rhodamine green.

15

Inhibition of Matrix Markers: Northern Blot Protocol

Data confirming activity in the enzyme assay was obtained as follows.

A498 renal epithelial carcinoma cell lines were obtained from ATCC and grown in EMEM medium supplemented with 10% fetal calf serum, penicillin (5 units/ml) and streptomycin (5ng/ml). A498 cells were grown to near confluence in 100mm dishes, serum-starved for 24 hours, pre-treated with compounds for 4 hours followed by a 10ng/ml addition of TGF-beta1 (R&D Systems, Inc., Minneapolis MN). Cells were exposed to TGF-beta1 for 24 hours. Cellular RNA was extracted by acid phenol/chloroform extraction (Chomczynski and Sacchi, 1987). Ten micrograms of total RNA were resolved by agarose gel electrophoresis and transferred to nylon membrane (GeneScreen, NEN Life Sciences, Boston MA). Membranes were probed with 32P-labeled cDNA probes (Stratagene, La Jolla, CA) for fibronectin mRNA. Membranes were exposed to phosphorimaging plates and bands were visualized and quantified with ImageQuant software (Molecular Dynamics, Sunnyvale, CA).

30 Inhibition of Matrix Markers: Western Blot Protocol

Data confirming activity in the enzyme assay was obtained as follows.

Cells were grown to near confluence in flasks, starved overnight and treated with TGF-beta and compounds. Cells were washed at 24 or 48 hours after treatment with ice cold phosphate buffered saline, then 500 microliter of 2X loading buffer was added to plate and cells were scraped and collected in microcentrifuge tube. (2X loading buffer: 100 mM Tris-Cl, pH6.8, 4% sodium dodecyl sulfate, 0.2% bromophenol blue, 20% glycerol, 5% beta-mercapto-ethanol).

35


Cells were lysed in tube and vortexed. Sample was boiled for 10 minutes. 20 microliters of sample was loaded on 7.5% polyacrylamide gel (BioRad) and electrophoresed.

Size fractionated proteins in gel were transferred to nitrocellulose membrane by semidry blotting. Membrane was blocked overnight with 5% powdered milk in phosphate buffer saline (PBS) and 0.05% Tween-20 at 4 degrees C. After 3 washes with PBS/Tween membranes were
5 incubated with primary antibody for 4 hours at room temperature. After three washes with PBS/Tween membrane was incubated with secondary antibody for 1 hour at room temperature. Finally, a signal was visualized with ECL detection kit from Amersham.

The compounds of this invention generally show ALK5 receptor modulator activity
10 having IC₅₀ values in the range of 0.0001 to 10 μ M.

Claims:

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein R_1 is naphthyl, anthracenyl, or phenyl optionally substituted with one or more substituents selected from the group consisting of halo, C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkyl, C_{1-6} haloalkyl, $O-(CH_2)_m-Ph$, $S-(CH_2)_m-Ph$, cyano, phenyl, and CO_2R , wherein R is hydrogen or C_{1-6} alkyl and m is 0-3; or R_1 is phenyl or pyridyl fused with an aromatic or non-aromatic cyclic ring of 5-7 members wherein said cyclic ring optionally contains up to three heteroatoms, independently selected from N , O and S , and is optionally substituted by $=O$;

R_2 represents hydrogen, C_{1-6} alkyl, C_{1-6} alkoxy, phenyl, C_{1-6} haloalkyl, halo, NH_2 , $NH-C_{1-6}$ alkyl or $NH(CH_2)_n-Ph$ wherein n is 0-3;

R_3 represents C_{1-6} alkyl, $-(CH_2)_p-CN$, $-(CH_2)_p-COOH$, $-(CH_2)_p-CONHR_4R_5$, $-(CH_2)_pCOR_4$, $-(CH_2)_q(OR_6)_2$, $-(CH_2)_pOR_4$, $-(CH_2)_q-CH=CH-CN$, $-(CH_2)_q-CH=CH-CO_2H$, $-(CH_2)_p-CH=CH-CONHR_4R_5$, $-(CH_2)_pNHCOR_7$ or $-(CH_2)_pNR_8R_9$,

R_4 and R_5 are independently hydrogen or C_{1-6} alkyl;

R_6 is C_{1-6} alkyl;

R_7 is C_{1-7} alkyl, or optionally substituted aryl, heteroaryl, aryl C_{1-6} alkyl or heteroaryl C_{1-6} alkyl;

R_8 and R_9 are independently selected from hydrogen, C_{1-6} alkyl, aryl and aryl C_{1-6} alkyl;

p is 0-4;

q is 1-4;

one of X_1 and X_2 is N and the other is NR_{10} ; and

R_{10} is hydrogen, C_{1-6} alkyl, or C_{3-7} cycloalkyl;

provided that the compound is not:

- i) 2-[5-(2-methylphenyl)-2-propyl-1H-imidazol-4-yl]pyridine,
- ii) 2-[2-(1,1-dimethylethyl)-5-(4-methoxyphenyl)-1H-imidazol-4-yl]pyridine,
- iii) 2-[2-(1,1-dimethylethyl)-5-phenyl-1H-imidazol-4-yl]pyridine,
- iv) 2-[5-(3,5-dichlorophenyl)-2-methyl-1H-imidazol-4-yl]pyridine,
- v) 2-[5-(3,5-dimethylphenyl)-2-methyl-1H-imidazol-4-yl]pyridine,
- vi) 2-[5-(3,5-dimethylphenyl)-2-ethyl-1H-imidazol-4-yl]pyridine,
- vii) 2-[5-(3,5-dimethylphenyl)-2-amino-1H-imidazol-4-yl]pyridine,
- viii) 2-[5-(3,5-dimethylphenyl)-2-isopropyl-1H-imidazol-4-yl]pyridine,
- ix) 2-[5-(3,5-dimethylphenyl)-2-propyl-1H-imidazol-4-yl]pyridine, or
- x) 2-[5-(3,5-dimethylphenyl)-2-carboxamide-1H-imidazol-4-yl]pyridine.

2. A compound according to claim 1 wherein R_1 is phenyl optionally substituted with one or more substituents selected from the group consisting of halo, C_{1-6} alkoxy, C_{1-6} alkylthio, and cyano; or R_1 is phenyl or pyridyl fused with an aromatic or non-aromatic cyclic ring of 5-7 members wherein said cyclic ring optionally contains up to three heteroatoms, independently selected from N, O and S, and is optionally substituted by =O.
3. A compound according to claim 1 or 2 wherein R_2 is positioned ortho to the nitrogen of the pyridyl ring.
4. A compound according to any one of the preceding claims wherein R_3 is C_{1-6} alkyl or $(CH_2)_pNHCOR_7$ wherein R_7 is C_{1-7} alkyl, or optionally substituted aryl, heteroaryl, aryl C_{1-6} alkyl or heteroaryl C_{1-6} alkyl.
5. A compound according to any one of the preceding claims wherein R_{10} is hydrogen.
6. A compound according to claim 1 as defined in any one of Examples 1 to 71, or a pharmaceutically acceptable salt thereof.
7. A pharmaceutical composition comprising a compound according to any one of the preceding claims, but without provisos iv) to x), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.
8. A method of inhibiting the TGF- β signaling pathway in mammals, comprising administering to a mammal, comprising administering to a mammal in need of such treatment, a therapeutically effective amount of a compound according to any one of claims 1 to 6, but without provisos i) to x), or a pharmaceutically acceptable salt thereof.
9. A method for treating a disease selected from chronic renal disease, acute renal disease, wound healing, arthritis, osteoporosis, kidney disease, congestive heart failure, ulcers, ocular disorders, corneal wounds, diabetic nephropathy, impaired neurological function, Alzheimer's disease, trophic conditions, atherosclerosis, peritoneal and sub-dermal adhesion, any disease wherein fibrosis is a major component, and restenosis, comprising administering to a mammal in need of such treatment, a therapeutically effective amount of a compound according to any one of claims 1 to 6, but without provisos i) to x), or a pharmaceutically acceptable salt thereof.
10. A method for inhibiting matrix formation in mammals, comprising administering to a mammal, a therapeutically effective amount of a compound according to any one of claims 1 to 6, but without provisos i) to x), or a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 01/00736

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D401/04 C07D407/14 C07D401/14 C07D413/14 C07D409/14
 C07D471/04 C07D417/14 A61K31/44 A61K31/415
 //(C07D401/14,233:00,213:00),(C07D407/14,317:00,233:00,213:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, PAJ, WPI Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 00 06563 A (CLAIBORNE CHRISTOPHER F ;MERCK & CO INC (US); CLAREMON DAVID A (US) 10 February 2000 (2000-02-10) abstract; page 11; claims	1-10
Y	WO 99 03837 A (ORTO MCNEIL PHARMACEUTICAL INC) 28 January 1999 (1999-01-28) abstract; pages 6-7; claims	1-10
A	WO 93 14081 A (SMITHKLINE BEECHAM CORP) 22 July 1993 (1993-07-22) page 21; claims	1-10
A	WO 95 03297 A (SMITHKLINE BEECHAM CORP ;ADAMS JERRY LEROY (US); GALLAGHER TIMOTHY) 2 February 1995 (1995-02-02) pages 34-36; claims	1-10
	-/-	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the International filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

& document member of the same patent family

Date of the actual completion of the International search

15 May 2001

Date of mailing of the International search report

31/05/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Frelon, D

INTERNATIONAL SEARCH REPORT

Internat'l Application No

PCT/GB 01/00736

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 656 644 A (ADAMS JERRY LEROY ET AL) 12 August 1997 (1997-08-12) pages 58-59; claims ---	1-10
A	GALLAGHER T F ET AL: "Regulation of stress -induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase" BIOORGANIC & MEDICINAL CHEMISTRY, GB, ELSEVIER SCIENCE LTD, vol. 5, no. 1, 1997, pages 49-64, XP002094123 ISSN: 0968-0896 the whole document ---	1-10
A	DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; IFE, R. J. ET AL: "4-(2-Pyridyl)-5-phenylthiazoles as novel non-bicyclic reversible inhibitors of the gastric H ⁺ /K ⁺ -ATPase" retrieved from STN Database accession no. 123:275232 XP002167407 RN 163229-21-8 disclaimed & BIOORG. MED. CHEM. LETT. (1995), 5(6), 543-6 , ---	1
A	DE 22 21 546 A (CIBA-GEIGY AG) 16 November 1972 (1972-11-16) disclaimed examples 5,8 ---	1
X	PATENT ABSTRACTS OF JAPAN vol. 1997, no. 09, 30 September 1997 (1997-09-30) -& JP 09 124640 A (NIPPON SODA CO LTD), 13 May 1997 (1997-05-13) page(8)(CN-deriv. not disclaimed); table 1, ex. 2,3,5,6,10,11 disclaimed -----	1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 01/00736

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0006563 A	10-02-2000	AU 5234799 A US 6207687 B	21-02-2000 27-03-2001
WO 9903837 A	28-01-1999	AU 8757098 A EP 0994858 A US 6040320 A	10-02-1999 26-04-2000 21-03-2000
WO 9314081 A	22-07-1993	AU 3592393 A BG 98902 A BR 9305809 A CA 2127876 A CN 1083473 A CZ 9401688 A EP 0623126 A EP 0943616 A ES 2053401 A FI 943319 A HU 69714 A JP 7503017 T MX 9300141 A NO 942618 A NZ 249301 A OA 9963 A SK 83594 A US 5686455 A US 5916891 A ZA 9300213 A	03-08-1993 30-06-1995 18-02-1997 22-07-1993 09-03-1994 18-01-1995 09-11-1994 22-09-1999 16-07-1994 12-09-1994 28-09-1995 30-03-1995 29-07-1994 30-08-1994 25-06-1996 11-12-1995 08-03-1995 11-11-1997 29-06-1999 18-11-1993
WO 9503297 A	02-02-1995	AU 7629594 A US 5916891 A ZA 9405363 A	20-02-1995 29-06-1999 14-03-1995
US 5656644 A	12-08-1997	US 5916891 A	29-06-1999
DE 2221546 A	16-11-1972	CH 579072 A CH 561202 A AR 194594 A AR 198820 A AR 198658 A AR 195910 A AT 319939 B AT 319940 B AT 319941 B AT 316544 B AU 472065 B AU 4205572 A BE 783244 A CA 1012148 A CH 561716 A CH 561717 A CH 561718 A CS 181711 B CS 181745 B CS 181746 B CS 181747 B CY 936 A DD 97654 A ES 402563 A	31-08-1976 30-04-1975 31-07-1973 24-07-1974 15-07-1974 15-11-1973 10-01-1975 10-01-1975 10-01-1975 15-06-1974 13-05-1976 15-11-1973 10-11-1972 14-06-1977 15-05-1975 15-05-1975 15-05-1975 31-03-1978 31-03-1978 31-03-1978 31-03-1978 23-06-1978 12-05-1973 01-11-1975

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 01/00736

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 2221546 A		FI 57407 B	30-04-1980
		FR 2137740 A	29-12-1972
		GB 1381031 A	22-01-1975
		HK 61477 A	16-12-1977
		HU 164884 B	28-05-1974
		IE 36319 B	13-10-1976
		IL 39285 A	10-02-1975
		JP 56030352 B	14-07-1981
		KE 2796 A	06-01-1978
		MY 11878 A	31-12-1978
		NL 7206346 A	14-11-1972
		NO 137445 B	21-11-1977
		SE 405731 B	27-12-1978
		SU 456409 A	05-01-1975
		SU 502605 A	05-02-1976
		SU 489329 A	25-10-1975
		SU 489330 A	25-10-1975
		US 3940486 A	24-02-1976
		US 3929807 A	30-12-1975
		YU 17680 A	30-04-1981
		YU 83779 A, B	31-12-1980
		YU 123372 A, B	31-12-1980
		YU 264478 A, B	31-12-1980
		YU 264578 A, B	31-12-1980
		YU 264678 A, B	31-12-1980
JP 09124640 A	13-05-1997	NONE	

THIS PAGE BLANK (USPTO)